Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Y Mabs Therapeutics Inc's Business Segments
Y Mabs Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2025
Reportable Segments
1
Largest Segment
DANYELZA
Total Revenue
$ 19
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2025
- DANYELZA0%
Revenue by Reportable Segment - Q2 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| DANYELZA | $ 20 | - |
Revenue by Product & Service Category - Q2 FY2025
- Product0%
- Royalty10.1%
- License2.7%
Revenue by Product & Service Category - Q2 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 19 | - |
| Royalty | $ 2 | 10.1% |
| License | $ 1 | 2.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Y Mabs Therapeutics Inc
Ymabs Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company was founded in 2015 and is headquartered in New York City, New York.
Ymabs Therapeutics focuses on developing monoclonal antibodies that target specific cancer antigens with the goal of providing safer and more effective treatment options for patients. Monoclonal antibodies are laboratory-produced molecules that can mimic the immune system's ability to fight cancer cells.
The company's flagship product, naxitamab, is an anti-GD2 monoclonal antibody which has shown promising results in preclinical and clinical studies for the treatment of neuroblastoma, a rare and aggressive type of cancer that primarily affects children. Naxitamab received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Ymabs Therapeutics is also developing omburtamab, another anti-GD2 monoclonal antibody, for the treatment of central nervous system/leptomeningeal metastases of neuroblastoma. This therapy aims to address the spread of neuroblastoma to the brain and spinal cord. Omburtamab has shown promising results in clinical trials and has received Fast Track designation from the FDA.
In addition to its neuroblastoma pipeline, Ymabs Therapeutics is exploring the potential of its antibodies in other types of cancer, including osteosarcoma, desmoplastic small round-cell tumor, melanoma, and glioblastoma. The company's innovative approach involves leveraging the unique properties of its antibodies to specifically target cancer cells while sparing healthy cells, thereby minimizing side effects.
Ymabs Therapeutics operates with a focus on scientific innovation, rigorous clinical development, and a patient-centric approach. The company collaborates with academic institutions, pharmaceutical companies, and research organizations to advance its pipeline and accelerate the development of new treatments.
Overall, Ymabs Therapeutics is committed to improving the outcomes for patients with cancer through the development of novel antibody-based therapies. With its dedication to innovation and collaboration, the company aims to make significant contributions to the field of oncology and provide hope to patients and their families.
Ymabs Therapeutics focuses on developing monoclonal antibodies that target specific cancer antigens with the goal of providing safer and more effective treatment options for patients. Monoclonal antibodies are laboratory-produced molecules that can mimic the immune system's ability to fight cancer cells.
The company's flagship product, naxitamab, is an anti-GD2 monoclonal antibody which has shown promising results in preclinical and clinical studies for the treatment of neuroblastoma, a rare and aggressive type of cancer that primarily affects children. Naxitamab received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Ymabs Therapeutics is also developing omburtamab, another anti-GD2 monoclonal antibody, for the treatment of central nervous system/leptomeningeal metastases of neuroblastoma. This therapy aims to address the spread of neuroblastoma to the brain and spinal cord. Omburtamab has shown promising results in clinical trials and has received Fast Track designation from the FDA.
In addition to its neuroblastoma pipeline, Ymabs Therapeutics is exploring the potential of its antibodies in other types of cancer, including osteosarcoma, desmoplastic small round-cell tumor, melanoma, and glioblastoma. The company's innovative approach involves leveraging the unique properties of its antibodies to specifically target cancer cells while sparing healthy cells, thereby minimizing side effects.
Ymabs Therapeutics operates with a focus on scientific innovation, rigorous clinical development, and a patient-centric approach. The company collaborates with academic institutions, pharmaceutical companies, and research organizations to advance its pipeline and accelerate the development of new treatments.
Overall, Ymabs Therapeutics is committed to improving the outcomes for patients with cancer through the development of novel antibody-based therapies. With its dedication to innovation and collaboration, the company aims to make significant contributions to the field of oncology and provide hope to patients and their families.
Y-mAbs Therapeutics Inc. is a biotechnology company that focuses on the development and commercialization of novel antibody-based therapeutics, particularly for the treatment of cancer. The companys primary segments can be categorized based on their pipeline of products, research endeavors, and partnerships. Here’s an extensive look at the segments, products, and services offered by Y-mAbs Therapeutics:
Segments
1. Oncology Therapeutics Segment:
- This is the core segment for Y-mAbs, concentrating on developing therapies aimed at various types of cancers, particularly pediatric cancers. The company is known for designing monoclonal antibodies that target specific tumor-associated antigens.
2. Research & Development (R&D) Segment:
- A significant portion of Y-mAbss resources is dedicated to R&D. This includes preclinical and clinical development phases of new therapeutic candidates, as well as ongoing studies to expand the applications of existing products.
3. Commercialization Segment:
- This segment focuses on the marketing and distribution of approved products, ensuring that they reach healthcare providers and patients. Establishing partnerships with research institutions and healthcare organizations also falls under this category.
Products
1. Olaratumab (DANYELZA):
- This is one of the lead products developed by Y-mAbs. DANYELZA is specifically designed for the treatment of neuroblastoma, a common solid tumor in pediatric patients. Its a monoclonal antibody targeting the GD2 antigen, which is prevalent in neuroblastoma cells.
2. Naxitamab (currently in development):
- This is another monoclonal antibody that also targets GD2. It is in advanced stages of clinical development and has received Breakthrough Therapy Designation from the FDA for use in treating patients with relapsed/refractory neuroblastoma.
3. Other Antibody-Drug Conjugates (ADCs):
- Y-mAbs is involved in developing ADCs, which are targeted cancer therapies that combine antibodies with cytotoxic drugs. These conjugates are designed to deliver potent treatments directly to cancer cells while limiting damage to healthy cells.
4. Combination Therapies:
- The company is exploring combination therapies that incorporate their monoclonal antibodies with other types of treatments, including chemotherapy, immunotherapy, and radiation therapy, to enhance effectiveness against various cancers.
Services
1. Clinical Trials Management:
- Y-mAbs conducts and manages clinical trials to gather data on the safety and efficacy of their products. This involves patient recruitment, site management, data analysis, and regulatory reporting.
2. Collaborative Development Programs:
- The company often enters partnerships with other biotech firms, academic institutions, and research organizations to leverage complementary expertise and resources in the development of new therapeutics.
3. Regulatory Affairs Services:
- Y-mAbs engages in regulatory affairs to navigate the complex landscape of drug approval processes, ensuring compliance with FDA and other international health authorities. This includes preparing submissions for Investigational New Drug (IND) applications and New Drug Applications (NDA).
4. Educational and Support Services:
- The company provides educational resources for healthcare providers regarding the use of their therapeutics, aiming to enhance the understanding and application of their products in clinical settings.
5. Patient Support Initiatives:
- Y-mAbs also engages in initiatives to support patients and their families, offering resources for managing treatment journey and access to information about ongoing clinical trials and available therapies.
Conclusion
Y-mAbs Therapeutics Inc. is focused on delivering innovative cancer treatments, particularly for pediatric patients, through its research and development of monoclonal antibodies and antibody-drug conjugates. By fostering partnerships and maintaining a strong R&D pipeline, the company aims to make significant advancements in the oncology therapeutic landscape.
Segments
1. Oncology Therapeutics Segment:
- This is the core segment for Y-mAbs, concentrating on developing therapies aimed at various types of cancers, particularly pediatric cancers. The company is known for designing monoclonal antibodies that target specific tumor-associated antigens.
2. Research & Development (R&D) Segment:
- A significant portion of Y-mAbss resources is dedicated to R&D. This includes preclinical and clinical development phases of new therapeutic candidates, as well as ongoing studies to expand the applications of existing products.
3. Commercialization Segment:
- This segment focuses on the marketing and distribution of approved products, ensuring that they reach healthcare providers and patients. Establishing partnerships with research institutions and healthcare organizations also falls under this category.
Products
1. Olaratumab (DANYELZA):
- This is one of the lead products developed by Y-mAbs. DANYELZA is specifically designed for the treatment of neuroblastoma, a common solid tumor in pediatric patients. Its a monoclonal antibody targeting the GD2 antigen, which is prevalent in neuroblastoma cells.
2. Naxitamab (currently in development):
- This is another monoclonal antibody that also targets GD2. It is in advanced stages of clinical development and has received Breakthrough Therapy Designation from the FDA for use in treating patients with relapsed/refractory neuroblastoma.
3. Other Antibody-Drug Conjugates (ADCs):
- Y-mAbs is involved in developing ADCs, which are targeted cancer therapies that combine antibodies with cytotoxic drugs. These conjugates are designed to deliver potent treatments directly to cancer cells while limiting damage to healthy cells.
4. Combination Therapies:
- The company is exploring combination therapies that incorporate their monoclonal antibodies with other types of treatments, including chemotherapy, immunotherapy, and radiation therapy, to enhance effectiveness against various cancers.
Services
1. Clinical Trials Management:
- Y-mAbs conducts and manages clinical trials to gather data on the safety and efficacy of their products. This involves patient recruitment, site management, data analysis, and regulatory reporting.
2. Collaborative Development Programs:
- The company often enters partnerships with other biotech firms, academic institutions, and research organizations to leverage complementary expertise and resources in the development of new therapeutics.
3. Regulatory Affairs Services:
- Y-mAbs engages in regulatory affairs to navigate the complex landscape of drug approval processes, ensuring compliance with FDA and other international health authorities. This includes preparing submissions for Investigational New Drug (IND) applications and New Drug Applications (NDA).
4. Educational and Support Services:
- The company provides educational resources for healthcare providers regarding the use of their therapeutics, aiming to enhance the understanding and application of their products in clinical settings.
5. Patient Support Initiatives:
- Y-mAbs also engages in initiatives to support patients and their families, offering resources for managing treatment journey and access to information about ongoing clinical trials and available therapies.
Conclusion
Y-mAbs Therapeutics Inc. is focused on delivering innovative cancer treatments, particularly for pediatric patients, through its research and development of monoclonal antibodies and antibody-drug conjugates. By fostering partnerships and maintaining a strong R&D pipeline, the company aims to make significant advancements in the oncology therapeutic landscape.